Oulu University Hospital Enhances Leadership in Arrhythmia Care with Advanced Genesis Robotic Technology
Stereotaxis (NYSE: STXS) announced that Oulu University Hospital in Finland has successfully implemented and begun treating patients with the advanced Genesis Robotic Magnetic Navigation (RMN) System. The hospital, which has previously treated over 2,000 patients with earlier versions of the technology, is now enhancing its arrhythmia care capabilities in northern Finland.
The Genesis System represents a significant advancement in Robotic Magnetic Navigation technology for cardiac ablation procedures, offering robotic precision and safety in treating arrhythmias. This condition, affecting tens of millions globally, can lead to increased risks of stroke, heart failure, and sudden cardiac arrest if left untreated.
Dr. Jarkko Magga, Cardiac Electrophysiologist at Oulu University, highlighted that robotic technology has been important to their team's ability to provide superior care for complex cardiac arrhythmias over the past 15 years. The hospital's adoption of the Genesis System demonstrates their commitment to maintaining high-quality patient care standards.
Stereotaxis (NYSE: STXS) ha annunciato che l'Ospedale Universitario di Oulu in Finlandia ha implementato con successo e ha iniziato a trattare pazienti con l'avanzato Genesis Robotic Magnetic Navigation (RMN) System. L'ospedale, che in precedenza ha trattato oltre 2.000 pazienti con versioni precedenti della tecnologia, sta ora migliorando le sue capacità di cura delle aritmie nel nord della Finlandia.
Il Sistema Genesis rappresenta un significativo avanzamento nella tecnologia della Navigazione Magnetica Robotica per le procedure di ablazione cardiaca, offrendo precisione robotica e sicurezza nel trattamento delle aritmie. Questa condizione, che colpisce decine di milioni di persone a livello globale, può portare ad un aumento dei rischi di ictus, insufficienza cardiaca e arresto cardiaco improvviso se non trattata.
Il Dr. Jarkko Magga, Elettrofisiologo Cardiaco all'Università di Oulu, ha sottolineato che la tecnologia robotica è stata fondamentale per la capacità del loro team di fornire cure superiori per aritmie cardiache complesse negli ultimi 15 anni. L'adozione del Sistema Genesis da parte dell'ospedale dimostra il loro impegno a mantenere standard di assistenza di alta qualità per i pazienti.
Stereotaxis (NYSE: STXS) anunció que el Hospital Universitario de Oulu en Finlandia ha implementado con éxito y ha comenzado a tratar pacientes con el avanzado Genesis Robotic Magnetic Navigation (RMN) System. El hospital, que anteriormente ha tratado a más de 2.000 pacientes con versiones anteriores de la tecnología, ahora está mejorando sus capacidades de atención de arritmias en el norte de Finlandia.
El Sistema Genesis representa un avance significativo en la tecnología de Navegación Magnética Robótica para procedimientos de ablación cardíaca, ofreciendo precisión robótica y seguridad en el tratamiento de arritmias. Esta condición, que afecta a decenas de millones de personas a nivel global, puede aumentar el riesgo de accidente cerebrovascular, insuficiencia cardíaca y paro cardíaco súbito si no se trata.
El Dr. Jarkko Magga, Electrofisiólogo Cardíaco en la Universidad de Oulu, destacó que la tecnología robótica ha sido importante para la capacidad de su equipo de proporcionar atención superior para arritmias cardíacas complejas durante los últimos 15 años. La adopción del Sistema Genesis por parte del hospital demuestra su compromiso de mantener altos estándares de atención al paciente.
스테레오택시스 (NYSE: STXS)는 핀란드 오울루 대학 병원이 제네시스 로보틱 자기 내비게이션 (RMN) 시스템을 성공적으로 도입하고 환자 치료를 시작했다고 발표했습니다. 이 병원은 이전 버전의 기술로 2,000명 이상의 환자를 치료한 경험이 있으며, 현재 북부 핀란드에서 심장 부정맥 치료 능력을 강화하고 있습니다.
제네시스 시스템은 심장 절제술을 위한 로봇 자기 내비게이션 기술의 중요한 발전을 나타내며, 부정맥 치료에서 로봇의 정밀성과 안전성을 제공합니다. 이 상태는 전 세계 수천만 명에게 영향을 미치며 방치할 경우 뇌졸중, 심부전 및 갑작스러운 심장 마비의 위험을 증가시킬 수 있습니다.
오울루 대학의 심장 전기생리학자 장크코 마가 박사는 로봇 기술이 지난 15년 동안 복잡한 심장 부정맥에 대한 우수한 치료를 제공하는 팀의 능력에 얼마나 중요한지를 강조했습니다. 병원의 제네시스 시스템 채택은 고품질 환자 치료 기준 유지에 대한 그들의 약속을 보여줍니다.
Stereotaxis (NYSE: STXS) a annoncé que l'Hôpital Universitaire d'Oulu en Finlande a mis en œuvre avec succès et a commencé à traiter des patients avec le système avancé Genesis Robotic Magnetic Navigation (RMN). L'hôpital, qui a précédemment traité plus de 2 000 patients avec des versions antérieures de la technologie, améliore maintenant ses capacités de soins en arythmie dans le nord de la Finlande.
Le système Genesis représente une avancée significative dans la technologie de la navigation magnétique robotique pour les procédures d'ablation cardiaque, offrant précision robotique et sécurité dans le traitement des arythmies. Cette condition, qui affecte des dizaines de millions de personnes dans le monde, peut entraîner un risque accru d'accident vasculaire cérébral, d'insuffisance cardiaque et d'arrêt cardiaque soudain si elle n'est pas traitée.
Le Dr Jarkko Magga, électrophysiologiste cardiaque à l'Université d'Oulu, a souligné que la technologie robotique a été essentielle pour la capacité de son équipe à fournir des soins supérieurs pour des arythmies cardiaques complexes au cours des 15 dernières années. L'adoption du système Genesis par l'hôpital démontre leur engagement à maintenir des normes de soins de qualité pour les patients.
Stereotaxis (NYSE: STXS) gab bekannt, dass das Universitätsklinikum Oulu in Finnland erfolgreich das fortschrittliche Genesis Robotic Magnetic Navigation (RMN) System implementiert hat und mit der Behandlung von Patienten begonnen hat. Das Krankenhaus, das zuvor über 2.000 Patienten mit früheren Versionen dieser Technologie behandelt hat, verbessert nun seine Fähigkeiten zur Behandlung von Arrhythmien im Norden Finnlands.
Das Genesis-System stellt einen bedeutenden Fortschritt in der Technologie der Robotischen Magnetnavigation für kardiale Ablationsverfahren dar und bietet robotergestützte Präzision und Sicherheit bei der Behandlung von Arrhythmien. Diese Erkrankung, die weltweit Zig Millionen Menschen betrifft, kann unbehandelt zu einem erhöhten Risiko für Schlaganfall, Herzinsuffizienz und plötzlichen Herztod führen.
Dr. Jarkko Magga, Herz-Elektrophysiologe an der Universität Oulu, betonte, dass die Robotertechnologie in den letzten 15 Jahren wichtig für das Team war, um eine überlegene Behandlung komplexer Herzrhythmusstörungen zu gewährleisten. Die Einführung des Genesis-Systems durch das Krankenhaus zeigt ihr Engagement, hohe Standards in der Patientenversorgung aufrechtzuerhalten.
- Successful implementation of advanced Genesis RMN System in a major hospital
- Expansion into Finnish market with established partner (2,000+ previous treatments)
- Technology has been used to treat over 150,000 patients globally
- None.
Insights
The installation of the Genesis Robotic System at Oulu University Hospital represents an incremental business development rather than a material financial catalyst. While this deployment maintains Stereotaxis's presence in the Nordic market and showcases continued adoption of their latest technology, the revenue impact from a single installation is modest relative to STXS's
The strategic value lies in the hospital's extensive experience with over 2,000 previous robotic procedures, which validates the technology's long-term clinical utility. However, this is primarily a replacement/upgrade sale rather than expansion into a new account. The Nordic healthcare market, while sophisticated, represents a relatively small addressable market compared to major regions like the US, Western Europe and Asia.
For investors, this news reinforces STXS's competitive position in robotic cardiac ablation but doesn't materially change the company's near-term growth trajectory or financial outlook. The real value drivers remain broader commercial adoption in major markets and the development of next-generation technologies.
The Genesis System deployment highlights Stereotaxis's technological evolution in robotic magnetic navigation (RMN) for cardiac procedures. The system's key advantages include enhanced precision during catheter manipulation and improved safety profiles compared to manual approaches - critical factors for complex arrhythmia cases.
Particularly noteworthy is Oulu's 15-year track record with RMN technology and treatment of over 2,000 patients, demonstrating both the durability of the platform and physician loyalty to the technology. The upgrade to Genesis indicates confidence in Stereotaxis's latest innovations and suggests strong clinical outcomes with their previous systems.
From a medical technology perspective, this installation reinforces the growing role of robotics in complex cardiac procedures, especially for treating the tens of millions affected by arrhythmias globally. However, the broader challenge for Stereotaxis remains accelerating adoption rates and competing with traditional manual approaches that dominate the market despite their limitations.
ST. LOUIS, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at Oulu University Hospital in Finland have successfully treated the first patients using the advanced Genesis Robotic Magnetic Navigation (RMN) System from Stereotaxis.
Oulu University Hospital has significant experience pioneering the use of robotic technologies for the treatment of heart arrhythmias, having treated over 2,000 patients with original versions of the technology. The implementation of the latest Genesis System introduces significant advances in Robotic Magnetic Navigation technology to the northern regions of Finland. Robotic Magnetic Navigation introduces the benefits of robotic precision and safety to cardiac ablation, a common minimally invasive procedure to treat arrhythmias. Tens of millions of individuals worldwide suffer from arrhythmias – abnormal heart rhythms that result when the heart beats too quickly, too slowly, or with an irregular pattern. When left untreated, arrhythmias may significantly increase the risk of stroke, heart failure, and sudden cardiac arrest.
“For 15 years, advanced robotic technology has been essential to our team, allowing us to provide superior patient care for patients with complex cardiac arrhythmias,” said Dr. Jarkko Magga, Cardiac Electrophysiologist at Oulu University. “We are pleased to continue to provide the highest quality patient care with the precision and stability offered by the more advanced Genesis System.”
“We are proud to enhance and expand our partnership with Oulu University to ensure patients in Finland have access to leading cardiac care,” said David Fischel, Chairman and CEO of Stereotaxis. “We look forward to continuing to support their successful and impactful robotic heart rhythm practice.”
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.Stereotaxis.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and statements relating to our recent acquisition of APT, including any benefits expected from the acquisition, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.
Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly Peery
Chief Financial Officer
314-678-6100
Investors@Stereotaxis.com
FAQ
What is the significance of Oulu University Hospital implementing Stereotaxis (STXS) Genesis System?
How many patients have been treated with Stereotaxis (STXS) technology globally?
What medical conditions does the Stereotaxis (STXS) Genesis System treat?
How long has Oulu University Hospital been using Stereotaxis (STXS) robotic technology?
